Attovia Therapeutics
ATTO | NASDAQ
$14.72
-$0.41 (-2.71%)
At close: Nov 16, 2026, 4:00 PM ET
-2.71%
(1D)No price chart data available for 1D timeframe.
Rating
29
+4.0 ptsFundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #832/1021 (Top 81%)
Key Statistics
Market Data
Market Cap $673.12M
1D Range
14.26 15.22
52W Range
13.73 25.55
Valuation (TTM)
PE -8.18
PB 1.69
EV/EBITDA -3.32
Valuation (NTM)
Forward PE N/A
Forward PEG 0.20
Price Target $45.00
Cash Flow
FCF Yield -11.6%
SBC Adj. FCF Yield -12.0%
SBC Impact -2.9%
Margins
Gross Margin 32.9%
Operating Margin -5945.5%
FCF Margin -5442.8%
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y N/A |
N/A
FCF 3Y | 5Y N/A |
N/A
Returns
ROA -19.1%
ROE -58.9%
ROIC -21.3%
Financial Health
Net Cash
$395.94M
Current Ratio 34.66
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-3...
Sector Healthcare
Industry Biotechnology
Employees 44
IPO Date Aug 5, 2026
Website www.attovia.com
Fiscal Year n/a
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
2
Consensus
Buy
Price Target
$45.00
Upside
+205.71%
Buy (2)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove ATTO